Multiresistant bacteria and current therapy - The economical side of the story

European Journal of Medical Research

Volumn 15, Issue 12, 2010, Pages 571-576

  Wilke, M H ^a  

^a Dr Wilke GmbH Inspiringhealth   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; DORIPENEM; LINEZOLID; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BLOODSTREAM INFECTION; COST EFFECTIVENESS ANALYSIS; DRUG COST; ENDOCARDITIS; HEALTH CARE COST; HUMAN; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PNEUMONIA; PRACTICE GUIDELINE;

EID: 78650534390     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-15-12-571     Document Type: Article

References (52)

1. Köck R et.al, Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe, Euro Surveill. 2010 Oct 14;15(41):19688
2. Schweickert B et.al, The MRSA-Import in ICUs is an important predictor for the occurrence of nosocomial MRSA-cases, Clin Microbiol Infect. 2010 Oct 26. doi:10.1111/j.1469-0691.2010.03409.x. [Epub ahead of print]
3. Resch A, Wilke M, Fink C; The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals; Eur J Health Econ. 2009 Mar;10(1):287-97
4. Wernitz MH, Lenz C, Veit SK. Die Bedeutung von Infektionen durch multiresistente Staphylococcus aureus für das deutsche Gesundheitswesen - The (n)ever ending story? J Pharmakol Ther 2009:18;75-82
5. Ott E et.al, Costs of nosocomial pneumonia caused by meticillin-resistant Staphylococcus aureus, J Hosp Infect. 2010 Oct 14. [Epub ahead of print]
6. Filice GA, Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection, Infect Control Hosp Epidemiol. 2010 Apr;31(4):365-73
7. Dietrich ES, Berthold H, Jopp R, Schreier U, Gilge R, Bartmann P. Kosten einer leitli-niengerechten Arzneimitteltherapie in Deutschland. Gesundh ökon Qual manag 2005; 10:35-43 (Pubitemid 40288419)
8. Dietrich ES, Schmid M, Bucher A, Lemmen S, Frank U, Daschner FD. Kostenreduktion in der Antibiotika-Therapie. Krankenhauspharmazie 1998;19(6):287-92
9. Slama TG, Gram-negative antibiotic resistance: there is a price to pay, Crit Care. 2008;12 Suppl 4:S4. Epub 2008 May 21
10. Eandi M; Hospital management of complicated intra-abdominal infections: pharmacoeconomic evaluation.; J Chemother. 2009 Jul;21 Suppl 1:44-55
11. Kumar A et.al, Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.; Crit Care Med. 2006 Jun;34(6): 1589-96
12. Vallés J, Relio J, Ochagavía A, Garnacho J, Alcalá MA; Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival.; Chest. 2003 May;123(5):1615-24 (Pubitemid 36549784)
13. Rello J, Determinants of Choice and Prescription Patterns in Empiric Antibiotic Therapy for HAP/VAP, Eur Respir J. 2010 Sep 16. [Epub ahead of print]
14. Ballock RT, Newton PO, Evans SJ, Estabrook M, Farnsworth CL, Bradley JS; A comparison of early versus late conversion from intravenous to oral therapy in the treatment of septic arthritis.J Pediatr Orthop. 2009 Sep;29(6):636-42
15. Eachempati SR, Hydo LJ, Shou J, Barie PS ; Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?; J Trauma. 2009 May;66(5): 1343-8
16. Mertz D, Koller M, Haller P, Lampert ML, Plagge H, Hug B, Koch G, Battegay M, Flückiger U, Bassetti S; Outcomes of early switching from intravenous to oral antibiotics on medical wards.; J Antimicrob Chemother. 2009 Jul;64(1):188-99
17. Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR; Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis.; Arch Intern Med. 2001 Mar 12;161(5):722-7
18. Brady PW, Conway PH, Goudie A, Length of intravenous antibiotic therapy and treatment failure in infants with urinary tract infections, Pediatrics. 2010 Aug;126(2): 196-203. Epub 2010 Jul 12
19. Schuetz P et.al, Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial JAMA. 2009 Sep 9;302(10): 1059-66.
20. Hochreiter M et.al, Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial, Crit Care. 2009;13(3):R83. Epub 2009 Jun 3
21. Chastre J et.al, Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial, JAMA. 2003 Nov 19;290(19):2588-98
22. Micek ST et.al, Optimizing antibiotic treatment for ventilator-associated pneumonia, Pharmacotherapy. 2006 Feb; 26(2):204-13
23. Van Zanten ARH, Engelfriet PM, van Dillen K, van Veen M, Nuijten MJC, Poldermann KH. Importance of nondrug costs of intravenous antibiotic therapy. Critical Care 2003; 7: 420-21.
24. Cousins D: Improving safe medication practice. NHS National Patient Safety Agency. www.npsa.nhs.uk
25. Menendez R, Reyes S, Martinez R, de la CP, Manuel VJ, Vallterra J. Economic evaluation of adherence to treatment guidelines in nonintensive care pneumonia. Eur Respir J 2007 Apr;29(4):751-6. (Pubitemid 46554626)
26. Shorr AF et.al, Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia, Chest. 2006 Jul;130(1):93-100
27. Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to Vancomycin. Crit Care Med. 2004 Jan;32(1): 137-43.
28. Mullins CD, Hsu VD, Shorr A et al. Linezolid versus Vancomycin health and economic outcomes: a retrospective database study of 11,018 infection-related hospitalization treatment episodes. ECCMID 2009; Poster P-778.
29. McCollum M, Rhew DC, Parodi S; Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species.; Clin Ther. 2003 Dec;25(12):3173-89 (Pubitemid 38096154)
30. Schürmann D, Sorensen SV, De Cock E, Duttagupta S, Resch A; Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany.; Eur J Health Econ. 2009 Feb;10(1):65-79
31. Grau S, Rubio-Terrés C, Pharmacoeconomics of linezolid, Expert Opin Pharmacother. 2008 Apr;9(6):987-1000
32. Walkey AJ, O'Donnell MR, Wiener RS, Linezolid versus Glycopeptide Antibiotics for the Treatment of Suspected Methicillin-Resistant Staphylococcus Aureus Nosocomial Pneumonia: A Meta-Analysis of Randomized Controlled Trials, Chest. 2010 Sep 23. [Epub ahead of print]
33. Shorr AF, Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature, Pharmacoeconomics. 2007;25(9):751-68
34. Boldt J, Papsdorf M, Expensive modern therapy options in intensive care medicine in Germany- are they being used? Results of a questionnaire, Dtsch Med Wochenschr. 2005 Jan 21;130(3):87-91 (Pubitemid 40175125)
35. Fowler V et.al, Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus, N Engl J Med. 2006 Aug 17;355(7):653-65.
36. Seaton RA, Daptomycin: rationale and role in the management of skin and soft tissue infections, J Antimicrob Chemother. 2008 Nov;62 Suppl 3:iii15-23
37. Lodise TP Jr, McKinnon PS, Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes, Pharmacotherapy. 2007 Jul;27(7):1001-12
38. Krige JE, Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections, Curr Med Res Opin. 2007 Sep;23(9):2147-56
39. Davies SL, Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes, Pharmacotherapy. 2007 Dec;27(12): 1611-8.
40. Fossaceca C, Outcomes analysis of daptomycin use in a community hospital, Adv Ther. 2007 May-Jun;24(3):517-28 (Pubitemid 47295428)
41. Bhavnani SM et.al, Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis, Clin Infect Dis. 2009 Sep 1;49(5): 691-8
42. Amin A, Clinical and economic consequences of ventilator-associated pneumonia, Clin Infect Dis. 2009 Aug 15;49 Suppl 1:S36-43
43. Merchant S et.al, Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia, Clin Ther. 2008 Apr;30(4):717-33
44. Chastre J et.al, Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study, Crit Care Med. 2008 Apr;36(4): 1089-96.
45. Matthews SJ, Lancaster JW, Doripenem monohydrate, a broad-spectrum carbapenem antibiotic, Clin Ther. 2009 Jan;31(1):42-63
46. Kollef MH, Nathwani D, Merchant S, Gast C, Quintana A, Ketter N, Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators, Crit Care. 2010;14(3):R84. Epub 2010 May 10 46.
47. Doan TL et al., Tigecycline: a glycylcycline antimicrobial agentClin Ther. 2006 Aug;28(8):1079-106
48. Nicolau DP, Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline, Expert Opin Pharmacother. 2009 May;10(7):1213-22
49. Reygaert WC, Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline, Ther Clin Risk Manag. 2010 Sep 7;6:419-30
50. Mallick R, Sun S, Schell SR, Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin, Surg Infect (Larchmt). 2007 Apr;8(2):159-72
51. Bergallo C et.al, Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin, Diagn Microbiol Infect Dis. 2009 Jan;63(1):52-61
52. Ancona F, Economic impact simulation analysis of use of tigecycline, as appropriate, in first-course antibiotic therapy for complicated intra-abdominal infections in intensive care patients, Minerva Med. 2010 Oct;101(5): 319-8